#5-73E. Navigating Modern Treatment Decisions in Multiple Myeloma: From Quadruplets to T-Cell Redirection (NEJM, 2026)

How can clinicians navigate the increasingly complex therapeutic landscape of multiple myeloma as survival extends toward potential functional cures? This review establishes an individualized framework integrating 2025 IMS-IMWG genomic risk stratification, functional fitness, and measurable residual disease to guide quadruplet inductions and early T-cell redirecting therapies. While many risk-adapted strategies reflect expert consensus and evolving clinical trial data rather than long-term randomized proof, this guide provides a practical roadmap for sequencing CAR T-cell therapies and bispecific antibodies to optimize patient outcomes.

Citation: Tarek H. Mouhieddine, Kenneth C. Anderson. Treatment Decisions in Multiple Myeloma. New England Journal of Medicine. 2026. DOI: 10.1056/NEJMra2605253

URL: https://doi.org/10.1056/NEJMra2605253

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.